ION537, an antisense oligonucleotide (ASO) targeting YAP1 mRNA effectively hindered YAP expression in tumour xenografts24 and is currently being evaluated in a phase I clinical trial (NCT04659096), enrolling patients with solid malignancies. This evidence concerns the gene YAP1 and neoplasm.